The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
Thyrocare Technologies Limited has opened a diagnostic laboratory in Kurnool, Andhra Pradesh, in collaboration with Ameelio Healthcare Private Limited, expanding its presence in the state to three laboratories. Inaugurated by Piyush Singh, vice-president of Thyrocare Technologies, the facility is equipped to handle routine and specialised diagnostic tests. It is intended to serve patients and healthcare partners in Kurnool and neighbouring areas through affordable testing, timely sample processing and diagnostic report delivery. The expansion forms part of the company's strategy to extend its diagnostic network beyond major metropolitan markets and improve access to testing services in emerging regions. Rahul Guha, managing director and chief executive of API Holdings and Thyrocare Technologies, and Rajdeep Panwar, chief commercial officer of Thyrocare Technologies, said the company would continue to focus on affordability, service quality and timely reporting as it expands its reach.
Thyrocare Technologies Limited has opened a new diagnostic laboratory in Kurnool, Andhra Pradesh, in collaboration with Ameelio Healthcare Private Limited, on October 21, 2026, expanding its network in the state to three laboratories. The facility, inaugurated by Piyush Singh, vice-president of Thyrocare Technologies, is intended to improve access to routine and specialised diagnostic testing for patients and healthcare partners in Kurnool and surrounding regions.
The laboratory is supported by trained professionals and is equipped to meet a range of diagnostic testing requirements. According to the company, the facility will support sample processing and the delivery of diagnostic reports, enabling healthcare providers and patients in the region to access testing services locally.
The partnership with Ameelio Healthcare is expected to strengthen Thyrocare's presence in Kurnool and extend the availability of its diagnostic services across neighbouring areas. The company said the facility would focus on providing affordable testing and reliable diagnostic services to meet regional healthcare requirements.
The expansion is part of Thyrocare's broader strategy to increase its presence beyond major metropolitan centres and establish a more extensive diagnostic network across emerging markets. By adding facilities in regional centres, the company aims to improve the geographical reach of its testing services and address demand from patients and healthcare partners outside larger cities.
Rahul Guha, managing director and chief executive of API Holdings and Thyrocare Technologies, said access to reliable diagnostic services should not depend on geographical location. He stated that the Kurnool laboratory, established in collaboration with Ameelio Healthcare, would bring testing services closer to more communities. He added that the company's expansion efforts would continue to prioritise affordability and accessibility while addressing the diagnostic requirements of patients and healthcare partners.
Rajdeep Panwar, chief commercial officer of Thyrocare Technologies, said the Kurnool expansion reflected the company's efforts to strengthen its diagnostic network in emerging markets. He noted that the association with Ameelio Healthcare would help the company serve the region more effectively and improve access to dependable testing services. He also emphasised the importance of maintaining consistent quality standards, timely reporting and affordability as the network expands.
Thyrocare, listed on the National Stock Exchange under the symbol THYROCARE and on the Bombay Stock Exchange under code 539871, provides diagnostic testing services in India. The Kurnool facility adds to its existing presence in Andhra Pradesh as the company continues to expand its network beyond metropolitan markets.
The company has not disclosed the investment made in establishing the laboratory, its testing capacity or the number of tests it expects to process daily. Further operational details, including the range of specialised tests available at the facility, were not specified in the announcement.
17th Nov, 2026
16th Nov, 2026
15th Nov, 2026
15th Nov, 2026
15th Nov, 2026